CNBX PHARMACEUTICALS INC.: 10-Q filed 2020-07-14

Name: CNBX PHARMACEUTICALS INC.: 10-Q filed 2020-07-14
Creator: CNBX PHARMACEUTICALS INC.

What CNBX PHARMACEUTICALS INC. reported in its quarterly report filed 2020-07-14 (fiscal Q3 2020): 23 published measures, 69 facts as tagged in accession 0001683168-20-002257.

This filing

Form: 10-Q (quarterly report)
Filed: 2020-07-14
Fiscal period: fiscal Q3 2020
Accession: 0001683168-20-002257 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2020-05-31	5,528,176	USD
At 2019-08-31	15,183,166	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2020-05-31	5,098,038	USD
At 2020-02-29	3,115,492	USD
At 2019-08-31	14,744,292	USD
At 2019-05-31	19,317,582	USD
At 2019-02-28	17,967,997	USD
At 2018-08-31	2,645,523	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2020-05-31	357,629	USD
At 2019-08-31	265,982	USD
At 2019-05-31	493,501	USD
At 2018-08-31	1,393,608	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	-725,675	USD	92
2019-09-01 to 2020-05-31	-6,735,736	USD	274
2018-09-01 to 2019-08-31	1,132,970	USD	365
2019-03-01 to 2019-05-31	-547,449	USD	92
2018-09-01 to 2019-05-31	2,526,242	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-09-01 to 2020-05-31	-2,060,996	USD	274
2018-09-01 to 2019-05-31	-2,225,109	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	1,886	USD	92
2019-09-01 to 2020-05-31	4,950	USD	274
2019-03-01 to 2019-05-31	2,160	USD	92
2018-09-01 to 2019-05-31	7,785	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-09-01 to 2020-05-31	0	USD	274
2018-09-01 to 2019-05-31	7,217,277	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-09-01 to 2020-05-31	2,152,643	USD	274
2018-09-01 to 2019-05-31	-5,892,275	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2020-05-31	-12,899,543	USD
At 2019-08-31	-6,163,807	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2020-05-31	910,818	USD
At 2019-08-31	1,002,286	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	-690,514	USD	92
2019-09-01 to 2020-05-31	-2,372,738	USD	274
2019-03-01 to 2019-05-31	-779,522	USD	92
2018-09-01 to 2019-05-31	-2,323,859	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2020-05-31	1,589,050	USD
At 2019-08-31	4,306,934	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2020-05-31	430,138	USD
At 2019-08-31	438,874	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	692,400	USD	92
2019-09-01 to 2020-05-31	2,377,688	USD	274
2019-03-01 to 2019-05-31	781,682	USD	92
2018-09-01 to 2019-05-31	2,331,644	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	370,084	USD	92
2019-09-01 to 2020-05-31	1,280,533	USD	274
2019-03-01 to 2019-05-31	333,759	USD	92
2018-09-01 to 2019-05-31	1,065,986	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2020-05-31	135,080,441	shares
At 2019-08-31	134,498,775	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2020-05-31	15,372,310	USD
At 2019-08-31	15,300,250	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2020-05-31	-172,625	USD
At 2019-08-31	2,810,013	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	1,946,546	USD	92
2019-09-01 to 2020-05-31	-6,908,361	USD	274
2019-03-01 to 2019-05-31	439,650	USD	92
2018-09-01 to 2019-05-31	8,397,698	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	322,316	USD	92
2019-09-01 to 2020-05-31	1,097,155	USD	274
2019-03-01 to 2019-05-31	447,923	USD	92
2018-09-01 to 2019-05-31	1,265,658	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2019-09-01 to 2020-05-31	167,190	USD	274
2018-09-01 to 2019-05-31	142,009	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2020-03-01 to 2020-05-31	-35,161	USD	92
2019-09-01 to 2020-05-31	-4,362,998	USD	274
2019-03-01 to 2019-05-31	232,073	USD	92
2018-09-01 to 2019-05-31	4,850,101	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2019-09-01 to 2020-05-31	0	USD	274
2018-09-01 to 2019-05-31	7,294,266	USD	273

Inspect the source

Entity: CNBX PHARMACEUTICALS INC. / CIK 0001343009
Captured: 2026-09-20T07:54:32.519Z
SEC response SHA-256: 915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))